Variable | Early RA (pg/ml) | Long-standing RA (pg/ml) |
P
| Controls (pg/ml) |
---|
sTNFR1 | 1500a | 1900b | ns | 1200d |
 | (1300–1700) | (1600–2000) |  |  |
BN/GRP | 3000a | 1700b | <0.05 | 340e |
 | (2400–3300) | (430–2500) |  |  |
CGRP | 1500a | 820b | ns | 310e |
 | (1100–1600) | (510–1600) |  |  |
NPY | 610a | 900c | ns | 930f |
 | (370–890) | (700–1900) |  |  |
SP | 170a | 410b | <0.05 | 180g |
 | (150–300) | (320–440) |  |  |
VIP | 250a | 280b | ns | 290g |
 | (210–280) | (230–340) |  |  |
ESR | 20a | 32b | ns | nm |
 | (7 – 32) | (22 – 47) |  |  |
- Concentrations were measured using ELISA. Values are medians (and Q1–Q3). The ESR is also shown. P relates to long-standing RA versus early RA. an = 4; bn = 22; cn = 21; dsTNFR1 value in healthy controls according to the manufacturer; en = 4; fn = 2; gn = 11. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; nm, not measured; ns, not significant; RA, rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal peptide.